Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet?
Invited conference paper presented and published in conference proceedings

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Sarcomas are mesenchymal tumors of soft tissues and bone that are usually fatal when they progress beyond local control. Dating back to the 19th century, attempts have been

made to treat sarcomas with immunotherapy. These attempts were either with highly toxic Coleys toxins or less potent vaccine therapies as well as unsuccessful trials with interferons. Interestingly, osteosarcoma was one of the first cancers to get regulatory approval with the immunotherapeutic agent mifamurtide L-MTPPE and is currently approved in Europe for use in combination with adjuvant chemotherapy.

With the advent of modern immune checkpoint inhibitors, several trials have since been completed and further are ongoing to test the safety and efficacy of immunotherapy in sarcomas. Owing to the significant heterogeneity of sarcomas, as well as our still somewhat limited understanding on the biology behind this group of diseases, the results of these trials have been a bit of a hit-and-miss.

During this talk, the successes and failures of developing immunotherapeutics in sarcomas will be highlighted, and whether immunotherapy truly holds the key to the future of deadly group of diseases will be discussed.
著者Loong Herbert Ho Fung
會議名稱Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
會議開始日18.07.2019
會議完結日20.07.2019
會議地點Kyoto
會議國家/地區日本
會議論文集題名Annals of Oncology
出版年份2019
月份10
卷號30
期次Suppl 6
頁次vi68 - vi68
國際標準期刊號0923-7534
語言英式英語
關鍵詞Sarcoma

上次更新時間 2020-09-07 於 01:03